Answers are grounded in this paper and cite their sources.
Objective: To evaluate the efficacy, safety, and tolerability of two fixed-dose combinations (FDCs) of empagliflozin, sitagliptin, and metformin extended release (ER) with dapagliflozin, sitagliptin, and metformin ER FDC in patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin monotherapy. Materials and Methods: This was a multicenter ( n = 16), randomized, double-blind, active-controlled, phase III study (Clinical Trials Registry - India/2024/04/066077) conducted across India, between May 2024 and January 2025. The patients were randomized (1:1:1) to receive FDC of empagliflozin 10 mg/sitagliptin 100 mg/metformin 1000 mg ER (Arm A); empagliflozin 25 mg/sitagliptin 100 mg/metformin 1000 mg ER (Arm B); dapagliflozin 10 mg/sitagliptin 100 mg/metformin 1000 mg ER (Arm C). The primary endpoint was the mean change in glycated hemoglobin (HbA1c) at week 16. Secondary endpoints included changes in fasting plasma glucose (FPG) and postprandial glucose (PPG). Adverse events (AEs) were recorded as part of the safety assessment. Results: A total of 315 patients were included in the study: Arm A ( n = 104), Arm B ( n = 106), and Arm C ( n = 105). At week 16, Arm B (−1.77%) demonstrated a significant reduction in HbA1c compared to Arm A (−1.54%) and Arm C (−1.53%). Arm B (−49.51 mg/dL) also showed a significant reduction in FPG compared to Arms A and C. Changes in PPG, body weight, systolic blood pressure, and glycemic target attainment were comparable across arms. All treatments were well tolerated, with no serious AE or significant laboratory abnormalities. Conclusion: Both empagliflozin FDCs showed improvement in glycemic parameters and were well tolerated. Arm B demonstrated a significant reduction in HbA1c and FPG compared to other arms. Trial Registration: CTRI/2024/04/066077
No takes yet. Share an insight, caveat, or question.
Kumthekar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: